AmuletTM 360 Left Atrial Appendage Occluder is commercially available for use in select international markets. Check the regulatory status in your geography.
Go beyond good enough
Complete closure¹ tailored for virtually all anatomies.
Rise above compromise with unrivaled1-3*complete closure
The VERITAS study: pivotal data
100%
clinically relevant closure (<3mm)1
93.9%
complete closure (0mm)1
100%
primary effectiveness endpoint1
99.8%
implant success1
Dual-seal technology
Powered by dual-seal technology, the device conforms to virtually any anatomy—even challenging ones. The dual-seal mechanism offers complete closure.¹ Abbott is the only company with LAAO devices offering two methods of physical closure.
Conformable lobe
A lobe that fills or closes the appendage
Disc
A disc that creates a complete seal at the ostium and a smooth transition to the surrounding
Dual-seal design
Eliminates the need for oral anticoagulants (OACs)6
Reduces the risk of device-related thrombus (DRT)7,8
93.9%
complete closure
(0mm)1
Broad size range
Abbott offers more sizes than any other device on the market. The Amulet 360 device is approximately the size of a quarter, allowing for a precise fit across a broad range of Left Atrial Appendage anatomies and sizes.
Safety for today and tomorrow
The Amulet 360 device uses a greater number of shorter, stabilizing anchors arranged in two rows instead of just one. The result is the same engagement with reduced procedural depth into the anatomy.¹
Proven safety profile
The evidence validates a proven safety and performance profile.
0%
primary safety endpoint1**
0.5%
pericardial effusion requiring drainage1
0%
device embolization1
Liberated from limits
The Abbott ecosystem is engineered to increase efficiency and streamline workflow without compromising performance.
96.1%
complete closure and increased procedural efficiency after only five cases9
AmuletTM 360 Left Atrial Appendage Occluder is commercially available for use in select international markets. Check the regulatory status in your geography.
*Based on comparison performance of Amulet 360 (VERITAS 45-day complete closure 93.9%) with publicly reported complete closure outcomes from published studies on other available LAAO devices, including PINNACLE FLX2 (90%) and OPTION3 (81%). Studies are not head-to-head and may involve different patient populations and other variables.
**VERITAS primary safety endpoint: composite of death, ischemic stroke, systemic embolism, or device/procedure-related complications requiring open cardiac surgery or major cardiovascular intervention through 7 days post-procedure or hospital discharge, whichever occurred later. Results are from a clinical study and may not be predictive of outcomes in all patients.
1. Nair D. Early outcomes with a next-generation dual-seal device for left atrial appendage closure: Results from the VERITAS Amulet 360 Pivotal study. Presented at: AF Symposium; February 6, 2026; Boston, MA, USA.
2. Kar, S., et al, Primary Outcome Evaluation of the Next Generation LAAC Device: Results from the PINNACLE FLX Trial, Circulation, 2021.
3. Saliba, W., Nair, D., Swarup, V., et al. (2025). Comparison of left atrial appendage closure and oral anti-coagulation after catheter ablation for atrial fibrillation: Concomitant and sequential cohorts of the OPTION randomized controlled trial. Heart Rhythm, 22(10), 2585-2594. https://doi.org/10.1016/j.hrthm.2025.04.029.
4. Zhong, Z., Gao, Y., Kovács, S., et al. (2024). Impact of left atrial appendage occlusion device position on potential determinants of devicerelated thrombus: a patientspecific in silico study. Clinical research in cardiology: official journal of the German Cardiac Society, 113(10), 1405–1418. https://doi.org/10.1007/s00392-023-02228-x
5. Bshennaty, A., Vogl, B. J., Saleh, G., et al. (2025). Comparison of Flow Dynamics After Left Atrial Appendage Occlusion With the Watchman FLX Versus Amulet Devices: Implications for Device-Related Thrombosis. Catheterization and cardiovascular interventions: official journal of the Society for Cardiac Angiography & Interventions, 106(4), 2084–2092. https://doi.org/10.1002/ccd.31710
6. Lakkireddy D, Thaler D, Ellis CR., et al. Amplatzer Amu let Left Atrial Appendage Occluder Versus Watchman Device for Stroke Prophylaxis (Amu let IDE): A Randomized, Controlled Trial. Circulation. .2.221;144.51543-.2552
7. Nielsen-Kudsk et al. Characterization and Clinical Outcomes of High-Risk Device-Related Thrombus in the Amu let IDE Trial. JACC EP. 2025 Jul;11(7):15.43-15.44.
8. Galea et al. Amulet or Watchman Device for Percutaneous Left Atrial Appendage Closure: Primary ResuIts of the SWISSAPERO Randomized clinical Trial. Circulation 2022 1.45:7.44.3738
9. Nair D, et al. Impact of Procedural Experience of a Next Generation Left Atrial Appendage Occlusion Device – Insights from the VERITAS Study. Presented at: NY Valves; June 26, 2026; New York, NY USA.
MAT-2677839 v1.0